MA34042B1 - Pyrrolo [2, 3. b ]pyridines qui inhibent la protéeine kinase raf - Google Patents

Pyrrolo [2, 3. b ]pyridines qui inhibent la protéeine kinase raf

Info

Publication number: MA34042B1
Authority: MA; Morocco
Prior art keywords: compounds; formulas; cancer; pyridines; pyrrolo
Prior art date: 2009-05-06

Application number

MA34424A

Other languages

Arabic (ar)

English (en)

French (fr)

Inventor

Prabha N Ibrahim

Wayne Spevak

Hanna Cho

Songyuan Shi

Guoxian Wu

Original Assignee

Plexxikon Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-05-06

Filing date

2010-05-04

Publication date

2013-03-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42236712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34042(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-05-04 Application filed by Plexxikon Inc filed Critical Plexxikon Inc

2013-03-05 Publication of MA34042B1 publication Critical patent/MA34042B1/fr

Links

102000001253 Protein Kinase Human genes 0.000 title abstract 2
108060006633 protein kinase Proteins 0.000 title abstract 2
RQMWVVBHJMUJNZ-UHFFFAOYSA-N 4-chloropyridin-2-amine Chemical compound NC1=CC(Cl)=CC=N1 RQMWVVBHJMUJNZ-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 5
150000003839 salts Chemical class 0.000 abstract 2
101150019464 ARAF gene Proteins 0.000 abstract 1
206010009944 Colon cancer Diseases 0.000 abstract 1
208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
206010033128 Ovarian cancer Diseases 0.000 abstract 1
206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
108091000080 Phosphotransferase Proteins 0.000 abstract 1
102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 abstract 1
108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 abstract 1
208000000453 Skin Neoplasms Diseases 0.000 abstract 1
208000024770 Thyroid neoplasm Diseases 0.000 abstract 1
206010046431 Urethral cancer Diseases 0.000 abstract 1
206010046458 Urethral neoplasms Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
238000011835 investigation Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
102000020233 phosphotransferase Human genes 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
201000000849 skin cancer Diseases 0.000 abstract 1
201000002510 thyroid cancer Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA34424A 2009-05-06 2010-05-04 Pyrrolo [2, 3. b ]pyridines qui inhibent la protéeine kinase raf MA34042B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US17605409P	2009-05-06	2009-05-06
PCT/US2010/033571 WO2010129567A1 (en)	2009-05-06	2010-05-04	Pyrrolo [2, 3. b] pyridines which inhibit raf protein kinase

Publications (1)

Publication Number	Publication Date
MA34042B1 true MA34042B1 (fr)	2013-03-05

Family

ID=42236712

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA34424A MA34042B1 (fr)	2009-05-06	2010-05-04	Pyrrolo [2, 3. b ]pyridines qui inhibent la protéeine kinase raf

Country Status (23)

Country	Link
US (3)	US8198273B2 (pt)
EP (2)	EP2427433A1 (pt)
JP (2)	JP2012526127A (pt)
KR (1)	KR20140014386A (pt)
CN (1)	CN102459262A (pt)
AR (1)	AR076749A1 (pt)
AU (1)	AU2010246005A1 (pt)
BR (1)	BRPI1013843A2 (pt)
CA (1)	CA2759997A1 (pt)
CL (1)	CL2011002739A1 (pt)
CR (1)	CR20110562A (pt)
EC (1)	ECSP11011437A (pt)
IL (1)	IL215908A0 (pt)
MA (1)	MA34042B1 (pt)
MX (1)	MX2011011737A (pt)
NI (1)	NI201100189A (pt)
NO (1)	NO20111508A1 (pt)
PE (1)	PE20120518A1 (pt)
RU (1)	RU2011149485A (pt)
SG (1)	SG175810A1 (pt)
TW (1)	TW201041888A (pt)
WO (2)	WO2010129570A1 (pt)
ZA (1)	ZA201108124B (pt)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA95244C2 (ru) *	2005-06-22	2011-07-25	Плексикон, Инк.	Соединения и способ модулирования активности киназ, и показания для их применения
WO2008063888A2 (en)	2006-11-22	2008-05-29	Plexxikon, Inc.	Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2009012283A1 (en)	2007-07-17	2009-01-22	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
WO2009143018A2 (en)	2008-05-19	2009-11-26	Plexxikon, Inc.	Compounds and methods for kinase modulation, and indications therefor
MY172424A (en)	2009-04-03	2019-11-25	Hoffmann La Roche	Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
US8329724B2 (en)	2009-08-03	2012-12-11	Hoffmann-La Roche Inc.	Process for the manufacture of pharmaceutically active compounds
CN106220623A (zh)	2009-11-06	2016-12-14	普莱希科公司	用于激酶调节的化合物和方法及其适应症
ES2627911T3 (es)	2009-11-18	2017-08-01	Plexxikon, Inc.	Derivados de N-[2-fluoro-3-(4-amino-7H-pirrolo[2,3-d]pirimidin-5-carbonil)-fenil]-4-bencenosulfonamida como moduladores de la proteína quinasa Raf para el tratamiento del cáncer
BR112012015745A2 (pt) *	2009-12-23	2016-05-17	Plexxikon Inc	compostos e métodos para a modulação de quinase, e indicações dos mesmos
TWI510487B (zh)	2010-04-21	2015-12-01	Plexxikon Inc	用於激酶調節的化合物和方法及其適應症
GB201007286D0 (en)	2010-04-30	2010-06-16	Astex Therapeutics Ltd	New compounds
GB201020179D0 (en)	2010-11-29	2011-01-12	Astex Therapeutics Ltd	New compounds
JP6112512B2 (ja) *	2010-12-01	2017-04-12	レクシファーマインコーポレイテッド	難治性癌を治療するための方法
WO2012106559A1 (en) *	2011-02-02	2012-08-09	Translational Genomics Research Institute	Biomarkers and methods of use thereof
US8889684B2 (en) *	2011-02-02	2014-11-18	Boehringer Ingelheim International Gmbh	Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
US9624213B2 (en) *	2011-02-07	2017-04-18	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (es) *	2011-02-21	2013-09-18	Plexxikon Inc	Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
CA2828940C (en)	2011-03-10	2024-04-16	Provectus Pharmaceuticals, Inc.	Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
WO2012138809A1 (en) *	2011-04-05	2012-10-11	Dawei Zhang	Heterocyclic compounds as kinase inhibitors
JP6113151B2 (ja)	2011-05-17	2017-04-12	プレキシコンインコーポレーテッドＰｌｅｘｘｉｋｏｎＩｎｃ．	キナーゼ調節およびその適応症
ES2725790T3 (es) *	2011-08-26	2019-09-27	Neupharma Inc	Algunas entidades químicas, composiciones, y métodos
CN102993199A (zh) *	2011-09-09	2013-03-27	山东轩竹医药科技有限公司	杂环取代的吡啶并吡咯激酶抑制剂
CN115403531A (zh)	2011-09-14	2022-11-29	润新生物公司	作为激酶抑制剂的化学实体、组合物及方法
US9249110B2 (en)	2011-09-21	2016-02-02	Neupharma, Inc.	Substituted quinoxalines as B-raf kinase inhibitors
US9249111B2 (en)	2011-09-30	2016-02-02	Neupharma, Inc.	Substituted quinoxalines as B-RAF kinase inhibitors
GB201118652D0 (en)	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
GB201118675D0 (en)	2011-10-28	2011-12-14	Astex Therapeutics Ltd	New compounds
GB201118656D0 (en)	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
GB201118654D0 (en)	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
EP2806874B1 (en)	2012-01-25	2017-11-15	Neupharma, Inc.	Quinoxaline-oxy-phenyl derivatives as kinase inhibitors
US9358235B2 (en)	2012-03-19	2016-06-07	Plexxikon Inc.	Kinase modulation, and indications therefor
JP6013029B2 (ja) *	2012-05-25	2016-10-25	千葉県	抗癌剤
GB201209609D0 (en)	2012-05-30	2012-07-11	Astex Therapeutics Ltd	New compounds
GB201209613D0 (en)	2012-05-30	2012-07-11	Astex Therapeutics Ltd	New compounds
JO3407B1 (ar)	2012-05-31	2019-10-20	Eisai R&D Man Co Ltd	مركبات رباعي هيدرو بيرازولو بيريميدين
US9150570B2 (en) *	2012-05-31	2015-10-06	Plexxikon Inc.	Synthesis of heterocyclic compounds
EA201590041A1 (ru) *	2012-07-03	2015-04-30	Ратиофарм Гмбх	Твердая форма холиновой соли вемурафениба
DE102012016908A1 (de) *	2012-08-17	2014-02-20	Aicuris Gmbh & Co. Kg	Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
TWI601725B (zh)	2012-08-27	2017-10-11	加拓科學公司	取代的氮雜吲哚化合物及其鹽、組合物和用途
EP2892534B8 (en)	2012-09-06	2021-09-15	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
US9688635B2 (en)	2012-09-24	2017-06-27	Neupharma, Inc.	Certain chemical entities, compositions, and methods
CN105712992B (zh) *	2012-09-29	2018-10-26	上海科州药物研发有限公司	作为cMet抑制剂的化合物及其制备方法和用途
WO2014075077A1 (en) *	2012-11-12	2014-05-15	Neupharma, Inc.	Certain chemical entities, compositions, and methods
JP2016500076A (ja) *	2012-11-20	2016-01-07	プリンシピアバイオファーマインコーポレイテッド	Ｊａｋ３阻害剤としてのアザインドール誘導体
MX365640B (es)	2012-12-21	2019-06-10	Plexxikon Inc	Compuestos y metodos para la modulacion de quinasas y sus indicaciones.
JP6199991B2 (ja) *	2013-01-18	2017-09-20	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	３置換ピラゾール及びｄｌｋ阻害剤としての使用
JP2016512518A (ja) *	2013-03-14	2016-04-28	ラシオファルムゲーエムベーハー	ベムラフェニブ塩酸塩の固体形態
US20140303121A1 (en)	2013-03-15	2014-10-09	Plexxikon Inc.	Heterocyclic compounds and uses thereof
DK2970265T3 (en)	2013-03-15	2018-10-01	Plexxikon Inc	HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
GB201307577D0 (en)	2013-04-26	2013-06-12	Astex Therapeutics Ltd	New compounds
CN105228983A (zh)	2013-05-30	2016-01-06	普莱希科公司	用于激酶调节的化合物及其适应症
WO2015075749A1 (en) *	2013-11-22	2015-05-28	Laurus Labs Private Limited	Novel processes for the preparation of vemurafenib
CZ2013943A3 (cs)	2013-11-27	2015-06-03	Zentiva, K.S.	Krystalické formy vemurafenibu
US9771369B2 (en)	2014-03-04	2017-09-26	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
HRP20210319T1 (hr)	2014-03-26	2021-04-30	Astex Therapeutics Ltd.	Kombinacije inhibitora fgfr i inhibitora igf1r
JO3512B1 (ar)	2014-03-26	2020-07-05	Astex Therapeutics Ltd	مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
RU2715236C2 (ru)	2014-03-26	2020-02-26	Астекс Терапьютикс Лтд	Комбинации
NO2714752T3 (pt) *	2014-05-08	2018-04-21
ES2774177T3 (es)	2014-09-15	2020-07-17	Plexxikon Inc	Compuestos heterocíclicos y usos de estos
TWI719960B (zh)	2015-02-10	2021-03-01	英商阿斯迪克治療公司	新穎組成物
US10478494B2 (en)	2015-04-03	2019-11-19	Astex Therapeutics Ltd	FGFR/PD-1 combination therapy for the treatment of cancer
WO2016164641A1 (en)	2015-04-08	2016-10-13	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
CZ2015250A3 (cs)	2015-04-14	2016-10-26	Zentiva, K.S.	Amorfní formy vemurafenibu
US10829484B2 (en)	2015-07-28	2020-11-10	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
GB201516504D0 (en)	2015-09-17	2015-11-04	Astrazeneca Ab	Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
ES2913048T3 (es)	2015-09-21	2022-05-31	Opna Immuno Oncology Sa	Compuestos heterocíclicos y usos de estos
US11155555B2 (en)	2015-09-23	2021-10-26	Janssen Pharmaceutica Nv	Compounds
EP3353164B1 (en)	2015-09-23	2021-11-03	Janssen Pharmaceutica, N.V.	Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
MX2018006856A (es)	2015-12-07	2018-08-01	Plexxikon Inc	Compuestos y metodos para modulacion de la quinasa, e indicaciones de los mismos.
ES2904615T3 (es)	2016-03-16	2022-04-05	Plexxikon Inc	Compuestos y métodos para la modulación de quinasas e indicaciones al respecto
WO2017218544A1 (en) *	2016-06-13	2017-12-21	Chemocentryx, Inc.	Methods of treating pancreatic cancer
US10195188B2 (en)	2016-06-13	2019-02-05	Chemocentryx, Inc.	Method of treating pancreatic cancer
CN107722013B (zh) *	2016-08-11	2021-01-12	中国科学院上海药物研究所	去氮嘌呤类化合物及其药物组合物、制备方法和用途
TW201815766A (zh)	2016-09-22	2018-05-01	美商普雷辛肯公司	用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
RU2765737C2 (ru)	2016-11-23	2022-02-02	Хемоцентрикс, Инк.	Способ лечения фокально-сегментарного гломерулосклероза
EP3558991A2 (en)	2016-12-23	2019-10-30	Plexxikon Inc.	Compounds and methods for cdk8 modulation and indications therefor
ES2928773T3 (es) *	2017-01-17	2022-11-22	Heparegenix Gmbh	Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
JP2020511467A (ja)	2017-03-20	2020-04-16	プレキシコンインコーポレーテッドＰｌｅｘｘｉｋｏｎＩｎｃ．	ブロモドメインを阻害する４−（１−（１，１−ジ（ピリジン−２−イル）エチル）−６−（３，５−ジメチルイソオキサゾール−４−イル）−１Ｈ−ピロロ［３，２−ｂ］ピリジン−３−イル）安息香酸の結晶形
WO2018226846A1 (en)	2017-06-07	2018-12-13	Plexxikon Inc.	Compounds and methods for kinase modulation
AU2018307910B2 (en)	2017-07-25	2024-07-25	Daiichi Sankyo Company, Limited	Formulations of a compound modulating kinases
RU2020113612A (ru)	2017-10-11	2021-11-12	Хемоцентрикс, Инк.	Лечение фокально-сегментарного гломерулосклероза антагонистами ccr2
US10717735B2 (en)	2017-10-13	2020-07-21	Plexxikon Inc.	Solid forms of a compound for modulating kinases
AU2018354423B2 (en)	2017-10-27	2024-11-07	Plexxikon Inc.	Formulations of a compound modulating kinases
TW202406538A (zh) *	2018-01-10	2024-02-16	美商克拉治療有限責任公司	包含苯基磺醯胺之醫藥組合物及其治療應用
NZ766594A (en)	2018-01-31	2025-12-19	Heparegenix Gmbh	Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
EP3768666A1 (en)	2018-03-20	2021-01-27	Plexxikon Inc.	Compounds and methods for ido and tdo modulation, and indications therefor
EP3810139A1 (en)	2018-06-21	2021-04-28	HepaRegeniX GmbH	Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
IL279641B2 (en) *	2018-07-16	2024-04-01	Heparegenix Gmbh	Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
PH12022551119A1 (en)	2019-12-10	2023-08-23	Hoffmann La Roche	New methylquinazolinone derivatives
CA3164361A1 (en)	2020-01-15	2021-07-22	Heparegenix Gmbh	3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as mkk4 inhibitors for treating liver diseases
WO2021222442A1 (en)	2020-04-29	2021-11-04	Plexxikon Inc.	Synthesis of heterocyclic compounds
JP2023530030A (ja)	2020-06-19	2023-07-12	シーフォーセラピューティクス，インコーポレイテッド	Ｂｒａｆ分解剤
WO2025108405A1 (zh) *	2023-11-22	2025-05-30	西藏海思科制药有限公司	作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2377318T3 (es) *	2002-09-06	2012-03-26	Cerulean Pharma Inc.	Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos
UA95244C2 (ru)	2005-06-22	2011-07-25	Плексикон, Инк.	Соединения и способ модулирования активности киназ, и показания для их применения
DE102005034406A1 (de)	2005-07-22	2007-02-01	Ratiopharm Gmbh	Neue Salze von Rosiglitazon
WO2008063888A2 (en)	2006-11-22	2008-05-29	Plexxikon, Inc.	Compounds modulating c-fms and/or c-kit activity and uses therefor
GB0624084D0 (en)	2006-12-01	2007-01-10	Selamine Ltd	Ramipril amino acid salts
PE20121126A1 (es) *	2006-12-21	2012-08-24	Plexxikon Inc	Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
WO2008079909A1 (en) *	2006-12-21	2008-07-03	Plexxikon, Inc.	Pyrrolo [2,3-b] pyridines as kinase modulators
WO2009012283A1 (en)	2007-07-17	2009-01-22	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor

2010
- 2010-04-30 TW TW099113997A patent/TW201041888A/zh unknown
- 2010-05-04 PE PE2011001867A patent/PE20120518A1/es not_active Application Discontinuation
- 2010-05-04 JP JP2012509906A patent/JP2012526127A/ja active Pending
- 2010-05-04 WO PCT/US2010/033576 patent/WO2010129570A1/en not_active Ceased
- 2010-05-04 CN CN2010800305090A patent/CN102459262A/zh active Pending
- 2010-05-04 AU AU2010246005A patent/AU2010246005A1/en not_active Abandoned
- 2010-05-04 WO PCT/US2010/033571 patent/WO2010129567A1/en not_active Ceased
- 2010-05-04 SG SG2011078979A patent/SG175810A1/en unknown
- 2010-05-04 BR BRPI1013843A patent/BRPI1013843A2/pt not_active IP Right Cessation
- 2010-05-04 KR KR1020117029018A patent/KR20140014386A/ko not_active Withdrawn
- 2010-05-04 EP EP10717980A patent/EP2427433A1/en not_active Withdrawn
- 2010-05-04 MX MX2011011737A patent/MX2011011737A/es not_active Application Discontinuation
- 2010-05-04 US US12/773,798 patent/US8198273B2/en active Active
- 2010-05-04 JP JP2012509907A patent/JP2012526128A/ja active Pending
- 2010-05-04 US US13/318,760 patent/US20120122860A1/en not_active Abandoned
- 2010-05-04 CA CA2759997A patent/CA2759997A1/en not_active Abandoned
- 2010-05-04 MA MA34424A patent/MA34042B1/fr unknown
- 2010-05-04 EP EP10717408A patent/EP2427462A1/en not_active Withdrawn
- 2010-05-04 RU RU2011149485/02A patent/RU2011149485A/ru not_active Application Discontinuation
- 2010-05-05 AR ARP100101517A patent/AR076749A1/es not_active Application Discontinuation
2011
- 2011-10-25 IL IL215908A patent/IL215908A0/en unknown
- 2011-10-26 CR CR20110562A patent/CR20110562A/es unknown
- 2011-11-01 EC EC2011011437A patent/ECSP11011437A/es unknown
- 2011-11-03 NI NI201100189A patent/NI201100189A/es unknown
- 2011-11-03 CL CL2011002739A patent/CL2011002739A1/es unknown
- 2011-11-03 NO NO20111508A patent/NO20111508A1/no not_active Application Discontinuation
- 2011-11-04 ZA ZA2011/08124A patent/ZA201108124B/en unknown
2012
- 2012-06-07 US US13/491,480 patent/US20120245174A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2759997A1 (en)	2010-11-11
US20100286142A1 (en)	2010-11-11
EP2427462A1 (en)	2012-03-14
BRPI1013843A2 (pt)	2016-04-12
AU2010246005A1 (en)	2011-12-01
CR20110562A (es)	2012-02-09
EP2427433A1 (en)	2012-03-14
SG175810A1 (en)	2011-12-29
WO2010129567A1 (en)	2010-11-11
JP2012526127A (ja)	2012-10-25
RU2011149485A (ru)	2013-06-20
ZA201108124B (en)	2014-04-30
ECSP11011437A (es)	2011-12-30
PE20120518A1 (es)	2012-05-24
NO20111508A1 (no)	2011-12-02
MX2011011737A (es)	2011-12-08
CN102459262A (zh)	2012-05-16
KR20140014386A (ko)	2014-02-06
CL2011002739A1 (es)	2012-04-09
US8198273B2 (en)	2012-06-12
NI201100189A (es)	2012-01-11
AR076749A1 (es)	2011-07-06
IL215908A0 (en)	2012-01-31
JP2012526128A (ja)	2012-10-25
TW201041888A (en)	2010-12-01
US20120122860A1 (en)	2012-05-17
US20120245174A1 (en)	2012-09-27
WO2010129570A1 (en)	2010-11-11

Publication	Publication Date	Title
MA34042B1 (fr)	2013-03-05	Pyrrolo [2, 3. b ]pyridines qui inhibent la protéeine kinase raf
MX2015013945A (es)	2015-12-11	Derivados de urea utiles como inhibidores de quinasa.
ECSP109953A (es)	2010-03-31	Derivados de piridazinona
BRPI0815572A2 (pt)	2015-02-18	Compostos e composições como inibidores de quinases
EA201070667A1 (ru)	2011-02-28	8-замещенные пиридо[2,3-в]пиразины и их применение
EA201100427A1 (ru)	2011-10-31	Гетероциклические ингибиторы киназы
MX2015002044A (es)	2016-01-22	Pirazolil-ureas como inhibidores de quinasa.
EA201001242A1 (ru)	2011-08-30	ПИРРОЛО[2,3-d]ПИРИДИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ
BR112015022011A2 (pt)	2017-07-18	derivados de imidazo[4,5-c]piridina e pirrolo[2,3-c] piridina como inibidores de ssao
EA201071089A1 (ru)	2011-04-29	Производные хиназолина как модуляторы raf-киназы и способы их применения
UA97506C2 (xx)	2012-02-27	Інгібітори полі(adp-рибозо)полімерази$ингибиторы поли(adp-рибозо)полимеразы
EA201691294A2 (ru)	2018-11-30	ГЕТЕРОАРИЛЗАМЕЩЕННЫЕ ПИРРОЛО[2,3-b]ПИРИДИНЫ И ПИРРОЛО[2,3-b]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
ATE534292T1 (de)	2011-12-15	Spiroverbindungen und anwendungsverfahren dafür
EA201100426A1 (ru)	2011-10-31	Бициклические ингибиторы киназы
UA111604C2 (uk)	2016-05-25	ЗАМІЩЕНІ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНОВІ СОЛІ
EA201070618A1 (ru)	2010-12-30	4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus
EA200600689A1 (ru)	2006-08-25	Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
PH12013501754A1 (en)	2013-10-14	Triazolopyridine compounds as pim kinase inhibitors
DE602006014579D1 (de)	2010-07-08	Heteroalkylgebundene pyrimidinderivate
WO2008121687A3 (en)	2008-11-20	Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
DE602004021838D1 (de)	2009-08-13	Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
MX342873B (es)	2016-10-17	Derivados de pirazolo-quinazolina sustituidos como inhibidores de cinasa.
MX2009012709A (es)	2009-12-08	Derivados de arileter-piridazinona.
MX2010009743A (es)	2010-09-28	Uso de derivados de pirimidina para el tratamiento de las enfermedades dependientes de los receptores del factor de crecimiento epidermico (egfr) o de enfermedades que hayan adquirido resistencia a los agentes que se dirigen a los miembros de la fami
MX374552B (es)	2025-03-06	Derivados de 2-fenil-3h-imidazo[4,5-b]piridina útiles como inhibidores de actividad de receptor huérfano similar a tirosina cinasa (ror1) de tirosina cinasa de mamífero.